Completed PHASE3 INTERVENTIONAL 2-arm NCT00091715

Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients With Mildly Symptomatic Pulmonary Arterial Hypertension (PAH)

Sponsor: Actelion

Conditions Pulmonary Hypertension

Interventions bosentan placebo

Updated 7 times since 2017 Last updated: Aug 26, 2011 Started: Apr 30, 2004 Primary completion: Nov 30, 2006 Completion: Feb 28, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00091715, this PHASE3 trial focuses on Pulmonary Hypertension and remains completed. Sponsored by Actelion, it has been updated 7 times since 2004, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Actelion

Data source: Actelion

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Ann Arbor, United States , Barcelona, Spain , Birmingham, United States , Bologna, Italy , Boston, United States , Brisbane, Australia , Calgary, Canada , Cambridge, United Kingdom , Camperdown, Australia and 22 more locations